Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128175 | 1.00 | HRH3 (0.59) | HRH3HDAC4FFAR1KCNH2EPHX2 | |
| SCHEMBL451175 | 1.00 | HRH3 (0.59) | HRH3HDAC4FFAR1KCNH2EPHX2 | |
| SCHEMBL15314478 | 1.00 | HRH3 (0.59) | HRH3HDAC4FFAR1KCNH2EPHX2 | |
| SCHEMBL27813823 | 0.89 | HRH3 (0.60) | HRH3HDAC4KCNH2KDM1AMAOA | |
| SCHEMBL23550031 | 0.87 | HRH3 (0.58) | HRH3HDAC4KCNH2KDM1AMAOA | |
| SCHEMBL27699501 | 0.87 | HRH3 (0.58) | HRH3HDAC4FFAR1KCNH2KDM1A | |
| SCHEMBL1476708 | 0.85 | FFAR1 (0.49) | HRH3FFAR1CYP3A4NAMPTIDO1 | |
| SCHEMBL12128172 | 0.83 | HRH3 (0.55) | HRH3HDAC4KCNH2KDM1AMAOA | |
| SCHEMBL451266 | 0.83 | HRH3 (0.55) | HRH3HDAC4KCNH2KDM1AMAOA | |
| SCHEMBL15314513 | 0.83 | HRH3 (0.55) | HRH3HDAC4KCNH2KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| EP-2805937-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2253615-B1 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2195293-B1 | CYCLOPTOPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-8063215-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| EP-2253615-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | HRH3 3/4885HDAC4 155/4885FFAR1 48/4885 |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | HRH4, HRH2, HRH3 | HRH3 3/4885HDAC4 162/4885FFAR1 43/4885 |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | HRH2, HRH4, HRH3 | HRH3 3/4885HDAC4 198/4885FFAR1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.